Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells

被引:20
作者
Tak, Eunyoung [1 ]
Jun, Dae Young [1 ]
Kim, Seok-Hwan [2 ]
Park, Gil-Chun [2 ]
Lee, Jooyoung [1 ]
Hwang, Shin [2 ]
Song, Gi-Won [2 ]
Lee, Sung-Gyu [2 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Div Liver Transplantat & Hepatobiliary Surg, Dept Surg,Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
基金
新加坡国家研究基金会;
关键词
Purinergic receptor P2Y2; hypoxia inducible factor-1 alpha; MRS2312; hepatocellular carcinoma; TRANSARTERIAL CHEMOEMBOLIZATION; ADENOSINE RECEPTORS; HYPOXIA; PROLIFERATION; PATHOPHYSIOLOGY; ANGIOGENESIS; ACTIVATION; SORAFENIB; MIGRATION; AGONISTS;
D O I
10.1177/0300060516662135
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: To examine if hypoxia inducible factor-1 alpha (HIF-1 alpha) can induce the upregulation of the purinergic receptor P2Y2 (P2Y2) and thereby promote the viability of human hepatocellular carcinoma (HCC) cells under hypoxic conditions. Methods: Archival HCC tumour specimens and corresponding non-cancerous tissues were examined immunohistochemically for P2Y2 protein. A series of in vitro experiments were undertaken using HCC cell lines to determine the effect of hypoxia on HIF-1 alpha and P2Y2 levels, the effect of HIF-1 alpha upregulation on P2Y2 levels, and the effect of P2Y2 upregulation on cell viability under hypoxic conditions. Results: Human HCC specimens were positive for P2Y2. Hypoxia and upregulated HIF-1 alpha both upregulated the P2Y2 levels in HCC cell lines. P2Y2 upregulation using plasmid transfection resulted in enhanced cell viability under hypoxia. Treatment of HepG2 cells with the selective P2Y2 antagonist MRS2312 downregulated P2Y2 and reduced cell viability in five HCC cell lines. P2Y2 knockdown reduced HepG2 cell viability under hypoxia. Conclusions: These present results suggest that HCC cells upregulate P2Y2 levels during hypoxia, which in turn promotes their growth. P2Y2 could be a potential therapeutic target for treating HCC.
引用
收藏
页码:1234 / 1247
页数:14
相关论文
共 49 条
  • [1] International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy
    Abbracchio, Maria P.
    Burnstock, Geoffrey
    Boeynaems, Jean-Marie
    Barnard, Eric A.
    Boyer, Jose L.
    Kennedy, Charles
    Knight, Gillian E.
    Fumagalli, Marta
    Gachet, Christian
    Jacobson, Kenneth A.
    Weisman, Gary A.
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 281 - 341
  • [2] Liver Ischemia/Reperfusion Injury: Processes in Inflammatory Networks-A Review
    Abu-Amara, Mahmoud
    Yang, Shi Yu
    Tapuria, Niteen
    Fuller, Barry
    Davidson, Brian
    Seifalian, Alexander
    [J]. LIVER TRANSPLANTATION, 2010, 16 (09) : 1016 - 1032
  • [3] Loss of P2Y2 Nucleotide Receptors Enhances Early Pathology in the TgCRND8 Mouse Model of Alzheimer's Disease
    Ajit, Deepa
    Woods, Lucas T.
    Camden, Jean M.
    Thebeau, Christina N.
    El-Sayed, Farid G.
    Greeson, Glen W.
    Erb, Laurie
    Petris, Michael J.
    Miller, Douglas C.
    Sun, Grace Y.
    Weisman, Gary A.
    [J]. MOLECULAR NEUROBIOLOGY, 2014, 49 (02) : 1031 - 1042
  • [4] Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors
    Alnouri, Mohamad Wessam
    Jepards, Stephan
    Casari, Alessandro
    Schiedel, Anke C.
    Hinz, Sonja
    Mueller, Christa E.
    [J]. PURINERGIC SIGNALLING, 2015, 11 (03) : 389 - 407
  • [5] Purinergic P2Y2 Receptors Promote Neutrophil Infiltration and Hepatocyte Death in Mice With Acute Liver Injury
    Ayata, Cemil Korcan
    Ganal, Stephanie C.
    Hockenjos, Birgit
    Willim, Karolina
    Vieira, Rodolfo P.
    Grimm, Melanie
    Robaye, Bernard
    Boeynaems, Jean Marie
    Di Virgilio, Francesco
    Pellegatti, Patrizia
    Diefenbach, Andreas
    Idzko, Marco
    Hasselblatt, Peter
    [J]. GASTROENTEROLOGY, 2012, 143 (06) : 1620 - +
  • [6] Hepatocellular carcinoma: clinical frontiers and perspectives
    Bruix, Jordi
    Gores, Gregory J.
    Mazzaferro, Vincenzo
    [J]. GUT, 2014, 63 (05) : 844 - 855
  • [7] Pathophysiology and therapeutic potential of purinergic signaling
    Burnstock, G
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (01) : 58 - 86
  • [8] Purinergic signalling: from discovery to current developments
    Burnstock, Geoffrey
    [J]. EXPERIMENTAL PHYSIOLOGY, 2014, 99 (01) : 16 - 34
  • [9] Purinergic signalling in the musculoskeletal system
    Burnstock, Geoffrey
    Arnett, Timothy R.
    Orriss, Isabel R.
    [J]. PURINERGIC SIGNALLING, 2013, 9 (04) : 541 - 572
  • [10] Burnstock Geoffrey, 2013, Keio Journal of Medicine, V62, P63, DOI 10.2302/kjm.2013-0003-RE